64375-41-3

Usage

Uses

Used in Pharmaceutical Industry:
1H-Benzimidazole-5-carboxylic acid, 2,3-dihydro-2-thioxo, methyl ester is used as a potential pharmaceutical compound for its unique structure and properties. It may exhibit biological activities that could be harnessed for therapeutic purposes, such as the development of new drugs or drug candidates.
Used in Material Chemistry:
In the field of material chemistry, 1H-Benzimidazole-5-carboxylic acid, 2,3-dihydro-2-thioxo, methyl ester is used as a building block for the synthesis of various organic compounds. Its unique structure allows for the creation of new materials with specific properties, such as improved stability, reactivity, or selectivity in chemical reactions.

InChI:InChI=1/C9H8N2O2S/c1-13-8(12)5-2-3-6-7(4-5)11-9(14)10-6/h2-4H,1H3,(H2,10,11,14)

Upstream product

• 75-15-0 carbon disulfide 
• 84445-93-2 methyl 4-(acetylamino)-3-aminobenzoate 
• 6313-39-9 4-acetamido-3-nitro-benzoic acid methyl ester 
• 36692-49-6 Methyl 3,4-diaminobenzoate 

Downstream Products

• 92807-01-7 5-hydroxymethyl-2-mercaptobenzoimidazole 
• 213685-19-9 6-(5-methoxycarbonylbenzimidazol-2-ylthio)-N-(2,6-diisopropylphenyl)hexanamide 
• 26663-77-4 methyl 1H-benzo[d]imidazole-5-carboxylate 

Relevant academic research and scientific papers

Substituted benzimidazole PI3K[alpha]/mTOR double-target inhibitor as well as pharmaceutical composition and application thereof

The invention discloses a substituted benzimidazole PI3K[alpha]/mTOR double kinase inhibitor as well as a pharmaceutical composition and application thereof. The substituted benzimidazole PI3K[alpha]/mTOR double kinase inhibitor comprises a compound shown in a general formula (I) or a stereoisomer, a geometrical isomer, a hydrate, a solvate, a pharmaceutically acceptable salt or a prodrug thereof,the substituted benzimidazole PI3K[alpha]/mTOR double kinase inhibitor and the pharmaceutical composition thereof provided by the invention can be used for inhibiting PI3K[alpha]/mTOR double kinase and acting on proliferative diseases related to the PI3K[alpha]/mTOR double kinase; and an inhibitor with a novel structure is provided for treating proliferative diseases with PI3K[alpha]/mTOR doublekinase.

Synthesis and antiprotozoal activity of novel 2-{[2-(1H-imidazol-1-yl) ethyl]sulfanyl}-1H-benzimidazole derivatives

A series of 19 new 2-{[2-(1H-imidazol-1-yl)ethyl]sulfanyl}-1H-benzimidazole derivatives was synthesized starting from the properly substituted 1,2-phenylendiamine. These compounds have hydrogen or methyl at position 1; while hydrogen, chlorine, ethoxy or methoxycarbonyl group is at position 5 and/or 6. The novel compounds were tested against protozoa Trichomonas vaginalis, Giardia intestinalis and Entamoeba histolytica. Experimental evaluations revealed strong activity for all tested compounds, having IC 50 values in the nanomolar range, which were even better than metronidazole, the drug of choice for these parasites.

Anticancer activity of hydrogen-bond-stabilized half-sandwich Ru II complexes with heterocycles

Neutral half-sandwich organometallic ruthenium(II) complexes of the type [(n6-cymene)RuCl2(L)] (H1-H10), where L represents a heterocyclic ligand, have been synthesized and characterized spectroscopically. The structures of five complexes were also established by single-crystal X-ray diffraction confirming a piano-stool geometry with n6 coordination of the arene ligand. Hydrogen bonding between the N-H group of the heterocycle and a chlorine atom attached to Ru stabilizes the metal-ligand interaction. Complexes coordinated to a mercaptobenzothiazole framework (H1) or mercaptobenzoxazole (H6) showed high cytotoxicity against several cancer cells but not against normal cells. In vitro studies have shown that the inhibition of cancer cell growth involves primarily G1-phase arrest as well as the generation of reactive oxygen species (ROS). The complexes are found to bind DNA in a non-intercalative fashion and cause unwinding of plasmid DNA in a cell-free medium. Surprisingly, the cytotoxic complexes H1 and H6 differ in their interaction with DNA, as observed by biophysical studies, they either cause a biphasic melting of the DNA or the inhibition of topoisomerase-IIα activity, respectively. Substitution of the aromatic ring of the heterocycle or adding a second hydrogen-bond donor on the heterocycle reduces the cytotoxicity. Copyright

Synthesis of N-Acetylbenzimidazole Derivatives

For the structure determination of thiazolobenzimidazol-3(2H)-one derivatives (2 or 3) they were converted to the corresponding 1-acetylbenzimidazoles (4) by desulfurization.The latter compounds (4) were alternatively prepared by the cyclization of 2-aminoacetanilide derivatives (5) with CS2 in dimethylformamide (DMF), followed by desulfurization with Raney Ni.However, the reactions of 5 with ethyl orthoformate/H2SO4 in DMF gave a mixture of 4 and its acetyl-rearranged product (7).Keywords-acetyl group; rearrangement; thiazolobenzimidazol-3(2H)-one; N-acetylbenzimidazoles; ethyl orthoformate; carbon disulfide; desulfurization